---
title: "Global Prosperity Remains a Buy on China Youzan (CHNVF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280018800.md"
description: "Global Prosperity analyst has reiterated a Buy rating on China Youzan (CHNVF), setting a price target of HK$0.19, while the stock closed at HK$0.12. The analyst consensus for China Youzan is Moderate Buy, with a target of HK$0.16, indicating a potential upside of 32.80%. Jefferies also maintains a Buy rating with a target of HK$0.17."
datetime: "2026-03-21T06:05:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280018800.md)
  - [en](https://longbridge.com/en/news/280018800.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280018800.md)
---

# Global Prosperity Remains a Buy on China Youzan (CHNVF)

Global Prosperity analyst maintained a Buy rating on China Youzan yesterday and set a price target of HK$0.19. The company’s shares closed last Wednesday at HK$0.12.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

China Youzan has an analyst consensus of Moderate Buy, with a price target consensus of HK$0.16, a 32.80% upside from current levels. In a report released on March 13, Jefferies also maintained a Buy rating on the stock with a HK$0.17 price target.

### Related Stocks

- [08083.HK](https://longbridge.com/en/quote/08083.HK.md)

## Related News & Research

- [Jefferies Sticks to Their Buy Rating for China Youzan (CHNVF)](https://longbridge.com/en/news/279163387.md)
- [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)
- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)